Two new studies further question Avandia safety

Share this article:

Two new studies have once again called into question the safety of GlaxoSmithKline's type 2 diabetes drug Avandia.

Both studies were published Sept. 11 in the Journal of the American Medical Association (JAMA).

One of the new studies, a meta-analysis co-authored by Dr. Steven Nissen of the Cleveland Clinic, found that Avandia rival drug, Takeda's Actos, appeared to protect patients from heart attacks, stroke and death by 18%. It was also Nissen who first published results of a meta-analysis in the New England Journal of Medicine in May that linked the Avandia to an increased risk of heart attack.

GSK has defended Avandia's safety with data from its own clinical trials and criticized Nissen's May meta-analysis methodology, which combined the results from different studies. 

The second of the two new studies published in JAMA backs up Nissen's earlier findings on Avandia. The second study, also a meta-analysis, was conducted by a team from Wake Forest University. The Wake Forest team found the Avandia increased the risk of heart attack by 42%. Nissen's earlier survey found a 43% increased risk.

GSK said in a statement posted on their Web site that the conclusions of the JAMA studies “do not confirm a difference in the safety profile of Avandia (rosiglitazone) and Actos (pioglitazone).” The statement added that the studies “do not yield data robust enough to guide doctors in selecting appropriate diabetes treatments for their patients.”

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.